DRUG - Betashares Global Healthcare Currency Hedged ETF

 

Why the Betashares Global Healthcare ETF – Currency-Hedged (ASX: DRUG) has slipped in 2025

Factor	What’s happening	Evidence
1. Under-performing global healthcare stocks	The sector has lagged broad equity benchmarks this year (-0.6 % YTD vs the S&P 500’s +8 %). Big-pharma names such as Pfizer, Johnson & Johnson and Roche – together almost half of DRUG’s portfolio – have been pressured by drug-price politics, looming patent-cliffs and faltering obesity-drug pipelines.	Bloomberg sector table (Bloomberg.com); FT coverage of drug-price crackdown & patent-cliff worries (Financial Times, Financial Times)
2. Currency-hedging drag	DRUG hedges USD, EUR, CHF etc. back to AUD. With the Aussie dollar up ~5 % YTD vs USD the hedge has worked (it shielded you from a stronger AUD), but it incurred a carry cost because US cash rates (≈ 5 ½ %) are still above Aussie rates (≈ 4 ¼ %). That negative “forward-points” cost is taken out of fund returns each day.	AUD spot +5.22 % YTD (Bloomberg.com); hedging mechanics in Betashares factsheet (uses daily forwards) (Betashares)
3. Large mid-year distribution	On 1 July 2024 the fund went ex-distribution for A$0.223 per unit and again (smaller) on 2 Jan 2025. Price charts that ignore reinvested cash make the drop look steeper than the total-return reality.	Distribution history table (Market Index)
4. Higher fees than peers	At 0.57 % p.a. DRUG’s management cost is > IXJ (0.43 %) or VHT (0.47 %). In a flat market fees bite more.	Key-facts section (Betashares)

Taken together, these explain why the unit price has slipped from A$8.81 (30 Jun 2024 close) to A$7.47 NAV (31 Jul 2025) – roughly -15 % on price, or -12 % total-return after adding back cash payouts. (Market Index)

---

Is it a good entry point?

Lens	What it tells us now
Valuation	MSCI World Healthcare forward P/E ≈ 15.9× vs its 10-yr average ~18× – the sector is not “cheap”, but it has de-rated to a post-COVID low. (MSCI)
Macro backdrop	Healthcare is defensive, yet 2025 rate-cut hopes have pushed investors back into cyclicals and tech. A US election season with heavy drug-price rhetoric could keep a lid on multiples until November.
Currency view	If you expect the AUD to stay firm or rise, the hedged class limits FX noise. If you think the AUD could fall back below US $0.65, the un-hedged IXJ ETF may rebound faster.
Sector catalysts	• US FDA decisions on GLP-1 obesity drugs (benefits Lilly/Novo, hurts others). • M&A pick-up as big-pharma reloads pipelines before 2028 patent cliffs. • Possible easing of US drug-price rhetoric after the election.

Bottom line

Pros

• Diversified exposure to >100 global healthcare giants in a single ASX trade.

• Currency hedge shelters you from AUD swings.

• Sector trading at a discount to its own 10-year average.

Cons

• Negative hedge carry (~0.6-0.8 % p.a.) plus 0.57 % fee.

• Political overhang on drug pricing could extend through the US election.

• Portfolio heavily concentrated in mega-cap pharma that are currently out of favour.

Long-term investors (3-5 yr horizon): a reasonable accumulation point if you want defensive, ageing-population exposure and prefer to keep currency risk minimal. Dollar-cost-averaging can soften further volatility.
Tactical traders (6-12 mo): momentum remains weak (Investing.com technical signal = “Strong Sell”) (Investing.com Australia); waiting for a clear price base, or buying the un-hedged IXJ if you expect AUD weakness, may offer better risk/reward.

(Always consider your own goals and talk to a licensed adviser before acting.)

---

Quick checklist before buying

1. Strategy fit – does a single-sector ETF suit your diversification plan?

2. Hedged vs un-hedged – outlook for AUD over your holding period.

3. Fee drag – 0.57 % plus hedging cost; total ~1.2 % in a flat year.

4. Re-invest distributions – to capture total return, not just price.

5. Position size & risk limits – healthcare ≈ 12 % of MSCI World; keeping DRUG around that weight avoids concentration risk.

Need a side-by-side sheet comparing DRUG with IXJ (un-hedged) and VHT (global healthcare un-hedged via Vanguard)? Let me know and I can spin up a quick table or tracker.